+ Watch MEIP
on My Watchlist
A development stage company, engaged in the clinical development of the anti-cancer drug phenoxodiol.
I bought 1000 shares @ 1.88 and will hold on tightI may attempt to take a few weeks off as well. It seems I used up the remainder of my dry powder on this buy (rookie mistake) and would be tempted to take some losses if bio dip continues.Good luck to all
My cumulative CAPS score for MEI is a victim of my matured strategy of holding on to winners even when I'm dubious about continued appreciation or the outcome of a catalyst. CAPS scoring is skewed to favor low entry prices, so in the long run it pays off scorewise to maintain the lowest possible entry price. For an example of how this improves score, see Hayrettin's profile. On the other hand, it will kill accuracy. Holding winners has allowed me to break out of the 3000's to my current level in the 7000's, but it didn't work for me with MEI this week.I was sufficiently dubious about the prospects of phase II trial of Pracinostat + Vidaza vs Vidaza in previously untreated high risk MDS to liquidate my real holdings for a profit as soon as the release of topline data became imminent. Among the red flags were MEI's long history of futility as Marshall Edwards, the low cost of the Pracinostat acquisition from S*Bio, and the wait for topline data until close to the end range of the timeline provided by the company.I'm terrible at estimating the volume of price drops on negative trials, and this one was no different. I thought the stock would rebound during Monday's session due to the other ongoing trials and strong cash backstop, so I started buying at 2.36 in the premarket. The stock instead continued to decline after the open and I did a better job of finding a bottom when I double down at 1.9. Zzporte now has 4000 shares cost basis 2.13. MEI has a market cap of 63M and cash of 79M as of the end of 2014. Topline data from a phase II trial of Pracinostat and Vidaza in elderly newly-diagnosed AML is expected in June. A phase II trial of Pracinostat with hypomethylating agent in second line MDS continues to enroll. Expansion cohorts of phase Ib trial of flavonoid ME344 with topotecan for solid tumors continue to enroll. MEI plans to initiate a phase I trial of PWT143 PI3K delta inhibitor in H1 2015.Don't get me wrong here. MEI is hardly a diamond in the rough. I expect their entire pipeline to eventually fail although who knows how long the company will continue to stink up the sector with new cheaply acquired candidates. On the other hand, it's historically been a fairly good bet to pick up stocks trading well under cash when they have a controlled burn, an active pipeline, and upcoming catalysts. However, if today's sector stumble was a headwind of downward momentum to come, it's hard to see where MEI might find a bottom.
should rebound and runup to AML data
Trading below cash... with future opportunities in the pipeline. I don't see this going much lower and will likely rebound
Undervalued, buy point $5.6
High Volume Breakout on 02/13/13
Did this go up for any logical reason?
It won't be fastest growing company but it will be one that steadily rises due to the fact the more and more people are trying to find the cure for cancer with any kind of research and development this company is ahead of some of the games that are being played right now. Anyone and everyone is throwing in their hats to get a piece of cancer research because of the fact that everyone wants to be recognized as the person or company that cured cancer.
Tharlow likes it...
Potential drug in pipeline for "orphan" cancer (orphan as per FDA) (pancreatic cancer) ref. news belowMany potential drugs are discarded during clinical test but a breaktrhrough drug can reaps substantial rewards!Therefore follow-up updates closely at every stage of clinical tests!-------------------------------------------------------NEW CANAAN, CT--(MARKET WIRE)--Mar 25, 2008 -- Triphendiol was recently granted orphan drug status by the U.S. Food and Drug Administration (FDA) for malignant melanoma and for the treatment of cholangiocarcinoma, bile duct cancer.
This company has a portfolio of next-generation cancer drugs with blockbuster potential. Look no further for the next Genentech.
Picked by GeezerRob
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions